All regulations
Nonrulemaking
FDA
Open for Comments
FDA-2026-P-3665
Requests that the FDA declare that the drug product, Oxaprozin Capsules, 600 mg is suitable for submission in an Abbreviated New Drug Application.
Documents
6
Comments
0
Key Dates
Comment Period OpensApr 3, 2026
Documents
| Type | Title | Status |
|---|---|---|
Supporting Material |
Keywords
CDER
Senores Pharmaceuticals Inc
Suitability Petition
declare that the
drug product Oxaprozin Capsules
600 mg is suitable for submission
in an Abbreviated New Drug Application
OPEN
Data from Regulations.gov